Pain Management Devices Market

Market Overview

The global Pain Management Devices Market was valued at approximately USD 5.2 billion in 2024 and is projected to reach USD 9.1 billion by 2033, growing at a CAGR of 6.3% during the forecast period (2025–2033).

Pain management devices are intended to alleviate chronic and acute pain through diverse mechanisms, including nerve stimulation, ablation or controlled drug infusion. These devices have application in neuropathic pain, cancer pain, musculoskeletal disorders or postoperative pain. Major technologies include spinal cord stimulators, TENS units, infusion pumps and radiofrequency ablation devices. The growing prevalence of chronic pain conditions, an aging worldwide population, and a greater emphasis on non-opioid and device-based pain therapy continue to drive demand for these devices. Additionally, developments in wearable and minimally invasive technology are allowing devices to be more accessible and effective, both in a clinical and home setting. The increasing awareness surrounding the risks of opioid dependency is increasing the use of pain management devices for safer long-term alternatives.

Market Dynamics

Market Drivers

Rising Prevalence of Chronic Pain Conditions

The growing prevalence of chronic pain conditions in the global population, including lower back pain, arthritis, neuropathy, and cancer-related pain, is a major factor impacting growth of the pain management devices market. Over 20% of the world population has chronic pain according to the World Health Organization (WHO), making it among the leading causes of long-term disability in the world.

Common chronic pain conditions in the aging population include osteoarthritis and fibromyalgia, while younger populations are affected by diabetic neuropathy and post-surgical pain. For example, in the United States, the Center for Disease Control and Prevention (CDC) estimates that approximately 50 million adults (1 in 5) live with chronic pain, with nearly 20 million suffering from high-impact chronic pain that limits their work and daily activities.

Clearly, there is a significant need for effective nonpharmacological pain management solutions based upon the prevalence of chronic pain. As opioid use faces greater scrutiny because of addiction and overdose concerns, device-based therapies, including spinal cord stimulators, radiofrequency ablation devices, and transcutaneous electrical nerve stimulation (TENS) units, are being considered safer and more sustainable alternatives.

For example, the growing utilization of pain management devices in oncology and hospice and palliative care settings for the management of cancer-related pain provides additional market expansion opportunities. For example, intrathecal infusion pumps are routinely used in advanced cancer patients for continuous targeted analgesia while reducing systemic opioid use.

Technological Advancements, Rising Healthcare Investments, and Aging Population

The improvements in medical device technology are fundamentally changing pain relief devices in terms of efficacy, safety, and user-friendliness with new devices such as MRI compatible neurostimulators, smaller and easier to use TENS units, rechargeable spinal cord stimulators, programmable infusion pumps, enhancing treatment specificity and user convenience.

A good example of this transformation is the Proclaim™ XR spinal cord stimulator recently cleared by the U.S. FDA, which provides a long battery life and can be programmed remotely using Bluetooth, changing the ways chronic pain can be treated outside of acute or clinical care; and the growth of investments in local healthcare systems worldwide are important enabler of that market. Global health spending reached over 10% of global GDP in 2021 (World Bank), and continued growth of public spending on digital health, chronic disease management, and procurement of medical devices will encourage demand for chronic pain therapies.

Countries such as India and Brazil are markedly increasing access to advanced pain medicine through public-private partnerships and/or national insurance programs. The increase in the elderly age demographic also enhances market growth potential. Older adults are at greater risk for chronic diseases, including osteoarthritis, spinal stenosis, and neuropathy.

The number of older people aged 60 and older is expected to increase from 1 billion in 2020 to 2.1 billion by 2050 (United Nations), creating more demand for pain-relieving devices. The population aged 80 and older is projected to triple by 2050, indicating a corresponding need for long-lasting, minimally invasive pain management options.

Market Restraint

Risk of Device-Related Complications and Safety Concerns

Although pain management devices are an advance in chronic and acute pain treatment, device-related complications remain a major barrier to expansion. These devices—like spinal cord stimulators, intrathecal pumps, and transcutaneous electrical nerve stimulation (TENS) units—can create risks as mild as skin irritation or as severe as surgical complications.

For example, implantable neurostimulation devices can lead to infection, electrode displacement, or nerve damage. Complications may require revision surgeries or device removal. A study in Neuromodulation: Technology at the Neural Interface reports the infection incidence for spinal cord stimulators is between 3% and 10%, which can carry enormous morbidity burdens.

In addition to the surgical risks, patients can experience inadequate pain control or develop tolerance over time, especially in long-term usage scenarios, leading to an overall perception of pain management being minimally effective. There are also concerns regarding mechanical failure, battery depletion, and any change for device malfunction.

All of these concerns may lead to the need for close monitoring post-procedure, resulting in higher healthcare costs, affecting physician motivation to treat a patient with one of the devices, and perhaps more importantly, patients and their concerns about these concerns may dissuade from pursuing a course of treatment with a pain management device. Fear of complications and limited clinical acceptance may deter adoption of a pain management device and integral in conservative or limited-resource care systems.

Segmental Analysis

The Pain Management Devices Market is segmented by product, by application and end-user. Each segment plays a significant role in alleviating different types of pain and improving patient outcomes through tailored therapeutic approaches.

By Product

In 2024, neurostimulation devices have the greatest share of the pain management devices, holding a 42.7% share of the market. This is due to their ubiquitous utilization in treating chronic pain (including, but not limited to sciatica, failed back surgery syndrome, and diabetic neuropathy). Spinal cord stimulators and TENS devices continue to be sought after because they can be non-invasive or minimally invasive, and provide long-term relief for chronic pain patients.

The continued prevalence of chronic pain disorders; the advancement of technologies, such as rechargeability and compatibility with MRIs; are all elements contributing to this growth. Ablation devices are the fastest growing product category as they are effective in treating localized pain, through the destruction of various nerves of interest.

Among the ablation procedures, radiofrequency ablation is in high demand for treating arthritis-related joint pain and lower back pain, impacting the increasing rate of radiofrequency ablation in both hospital and outpatient settings. Infusion pumps and analgesic patches have stable demand areas for patients that suffer with cancer and post-operative pain, due to the benefits of sustained pain relief and controlled medication delivery. These devices are likely to be used in homecare and palliative care settings.

By End-User

Hospitals are the largest end-user segment, and they accounted for 53.6% of the total market share in 2024. Hospitals provide the site for the most complicated and challenging pain-management procedures, including spinal cord stimulator placement and radiofrequency ablation. It is likely that as hospital admissions for chronic diseases and elective surgeries rise, demand for pain management devices in hospitals will also remain strong.

Ambulatory Surgical Centers (ASCs) are on the rise in the pain management community and are expected to take an increasing share of the pain management market. ASCs allow for same-day, cost-effective treatments that are appropriate to outpatient pain procedures. The popularity of new, minimally invasive treatments will continue to drive the uptake of devices in ASCs. Home Healthcare is also a growing segment, due to increasing demand for home-based therapies, particularly among the elderly who require pain therapies.

Devices such as TENS units and infusion pumps are being more frequently used at home, because of designs that allow for easy use and remote monitoring capabilities. The trend toward home health care aligns with a larger trend toward decentralization aimed at improving patients’ comfort and satisfaction with treatments.

By Application

With a 34.8% share of the market in 2024, Neuropathic Pain has the most significant share primarily due to the increasing prevalence of diabetes, shingles, multiple sclerosis and chemotherapy-induced peripheral neuropathy. Nerve pain, whether from damaged or dysfunctional nerves, can be difficult to treat solely with pharmacological treatments, making devices such as spinal cord stimulators and TENS units especially helpful to patients experiencing neuropathic pain.

The increasing number of lifestyle diseases as well as growing aging population are major contributors to the expansion of this segment because, oftentimes, neuropathic pain becomes chronic and debilitating. Cancer Pain is another application segment with growing demand, especially in oncology and palliative care.

Devices like intrathecal infusion pumps and nerve ablation systems are increasingly employed to manage pain in patients undergoing chemotherapy or with metastatic disease. As the worldwide burden of cancer gains momentum as well as the impetus to improve quality of life in patients with advanced disease, this segment can expect strong growth. Musculoskeletal Pain is expected to have steady growth, reflecting the increasing incidence of arthritis, low back pain, and sports-related injuries.

Ablation and neurostimulation products are often used in orthopedic and rehabilitation clinics to treat chronic joint and muscle pain, especially in elderly and physically active groups. Heads Up! Facial & Migraine Pain is starting to receive more focus, for many reasons including rising numbers of migraines diagnosed globally. TENS or implantable stimulators to cranial nerves are offering relief to patients who have not responded to traditional therapies. Wearable neurostimulation technology is creating new access to pain management solutions for migraines or trigeminal neuralgia.

Regional Analysis

North America

In 2024, North America is expected to have the highest share of the market at 38.9%. This is driven by a high prevalence of chronic pain and the early adoption of new medical technologies. The United States is also the largest contributor; the U.S. has many of the largest medical technology companies, such as Medtronic, Abbott, and Boston Scientific.

According to the CDC, ~20% of U.S. adults have chronic pain, and chronic pain is the leading cause of disability in the U.S. The region has favorable reimbursement structures, established pain management clinics, and an ongoing push away from opioids. Other driving technologies include MRI-compatible spinal cord stimulators, the ability to program devices remotely, and the ability to program multiple devices simultaneously.

Europe

Europe is a substantial market that includes countries such as Germany, the United Kingdom, France, and the Netherlands, where there are strong contributions to the market. The market growth in this region is largely supported by an acute burden of musculoskeletal disorders, cancer, and diabetes-related neuropathy.

Most recent statistics from the European Pain Federation claim that almost 20% of Europeans suffer from chronic pain, and that there are many undertreated instances. Various governmental initiatives to advance pain management plus more device-based therapies offered through national health care systems will drive market growth. In addition, an aging population and a focus on improving quality of life are all contributors that will provide long-term demand dynamics.

Asia-Pacific

The Asia-Pacific region is anticipated to express the fastest growth, projected with a CAGR of 7.8% for the years 2025–2033. Rapid urbanization, new levels of healthcare expenditures, and demand for enhanced awareness surrounding chronic pain management solutions will drive a significant portion of this growth.

Countries like China, Japan, South Korea, and India will lead the growth. For example, Japan has a high demand for neurostimulation and ablation devices due to its elderly population, with a high incidence of arthritis and back pain. At the same time, India and China are both seeing increasing hospital infrastructure investments and improving hospital and device availability through public and private partnerships, further increasing expansion capabilities in urban and semi-urban areas.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are experiencing moderate growth due to healthcare investment and an increasing focus on the management of chronic disease. Brazil and Mexico are the leading markets in Latin America, driven by factors such as further growth of the private healthcare sector and a wider recognition of the need for cancer related pain management.

The Middle East & Africa markets are developing slowly due to ongoing efforts to modernize healthcare systems in the UAE, Saudi Arabia, and South Africa, as well as other multi-national efforts. Nevertheless, access to advanced medical technologies and affordability remain important hurdles to more widespread access to healthcare across many parts of these regions.

Recent Development

1. April 2024 – Medtronic: Launched Inceptiv™, a closed-loop spinal cord stimulator that adjusts in real time based on spinal signals.
2. February 2025 – Medtronic: Received FDA approval for BrainSense™ Adaptive DBS, the first brain-responsive stimulation system.
3. March 2025 – Abbott: Clinical study showed Proclaim™ XR SCS provides full pain relief with under 6 hours of daily use.